Procédé inductif d'enduction métallique de fibres par voie liquide

In order to strengthen the main materials used in aeronautics, the community has long been oriented towards the development of metal matrix composites (MMC).During this thesis, it was developed a new method for coating with a liquid metal alloy, ceramic fibers that are involved in the manufacture of the composite.Using the technique of inductive heating to allow melting of the alloy, deposition by liquid way is made possible, while preserving the initial composition of the most complex alloys. With this new route, deposit rates are obtained very high compared with other existing methods, then this leaves glimpse to high productivity for the future.En vue de renforcer les principaux matériaux utilisés dans l’aéronautique, la communauté s’est depuis longtemps orientée vers l’élaboration de composites à matrice métallique (CMM). Durant cette thèse, il a été développé un nouveau procédé permettant l’enduction, par un alliage métallique liquide, de fibres céramiques qui entrent en jeu dans la fabrication du composite. En utilisant la technique du chauffage inductif pour permettre la fusion de l’alliage, le dépôt par la voie liquide est rendu possible, tout en préservant la composition initiale des alliages les plus complexes. Grâce à cette nouvelle voie, on obtient des vitesses de dépôt très élevées au regard des autres procédés existants, ceci laisse alors entrevoir une forte productivité pour le futur

Capecitabine-induced-coronary-vasospasm leading to polymorphic ventricular tachycardia and cardiac arrest

Abstract Capecitabine, a pro-drug of 5-fluorouracil, is commonly used in the treatment of breast and colorectal cancer. Its side effects, including nausea, vomiting, diarrhea, fatigue, loss of appetite, and bone marrow suppression, are well recognized. However, coronary vasospasm represents a less commonly recognized but significant complication of fluoropyrimidine-based therapies such as capecitabine. Proposed mechanisms for this adverse effect complication include direct endothelium-independent vasoconstriction, activation of protein kinase C, and activation of the cyclooxygenase pathway. In this report, we present a case of capecitabine-induced coronary vasospasm leading to progressive, focal ST-elevations, myocardial ischemia, and subsequently polymorphic ventricular tachycardia. These events were captured on telemetry, in a male in his early 40s, diagnosed with stage IIIB sigmoid colon cancer. Notably, the patient had no pre-existing coronary artery disease or other cardiovascular risk factors. Upon diagnosis, the patient was initiated on a calcium channel blocker, verapamil, to mitigate further coronary vasospasm events. After thorough discussions that prioritized the patient’s input and values, an implantable cardioverter-defibrillator was placed subcutaneously. Following discharge, the patient restarted capecitabine therapy along with verapamil prophylaxis and did not experience any subsequent shocks from his ICD as assessed during his outpatient follow-up visits. This case emphasizes the need to involve patients in decision-making processes, especially when managing unexpected and serious complications, to ensure treatments align with their quality of life and personal preferences